Fintel reports that on September 18, 2023, HC Wainwright & Co. initiated coverage of Anebulo Pharmaceuticals (NASDAQ:ANEB) with a Buy recommendation.
Analyst Price Forecast Suggests 155.00% Upside
As of August 31, 2023, the average one-year price target for Anebulo Pharmaceuticals is 8.16. The forecasts range from a low of 8.08 to a high of $8.40. The average price target represents an increase of 155.00% from its latest reported closing price of 3.20.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Anebulo Pharmaceuticals is 0MM. The projected annual non-GAAP EPS is -0.57.
What is the Fund Sentiment?
There are 17 funds or institutions reporting positions in Anebulo Pharmaceuticals. This is an increase of 2 owner(s) or 13.33% in the last quarter. Average portfolio weight of all funds dedicated to ANEB is 0.43%, a decrease of 28.56%. Total shares owned by institutions increased in the last three months by 2.74% to 7,039K shares.
What are Other Shareholders Doing?
22nw holds 5,066K shares representing 19.76% ownership of the company. No change in the last quarter.
LVW Advisors holds 672K shares representing 2.62% ownership of the company. In it's prior filing, the firm reported owning 673K shares, representing a decrease of 0.15%. The firm decreased its portfolio allocation in ANEB by 20.39% over the last quarter.
Nantahala Capital Management holds 511K shares representing 1.99% ownership of the company. No change in the last quarter.
Mangrove Partners holds 399K shares representing 1.56% ownership of the company. No change in the last quarter.
Praetorian PR holds 180K shares representing 0.70% ownership of the company.
Anebulo Pharmaceuticals Background Information
(This description is provided by the company.)
Anebulo is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well tolerated and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
